Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyHighmark WV preferred oncology products Policy Upd…
    Ask Trek AI about this page
    CurrentHighmark West VirginiaPolicy N/A

    Preferred Oncology Products (biosimilars and supportive care agents) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Highmark West Virginia policy alerts

    Know when Highmark West Virginia releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Highmark West Virginia preferred and non-preferred oncology products (including biosimilars and supportive care agents) and describes prior authorization and therapeutic trial expectations for non-preferred requests; applies to professional and facility claims.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerHighmark West Virginia
    PolicyPreferred Oncology Products (biosimilars and supportive care agents) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor non-preferred oncology products submit prior authorization with documentation of an adequate therapeutic trial (typically six months) and evidence of failure or intolerance to preferred products.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsAdequate trial definition
    180 daysNew therapy window
    multipleProduct listings
    all marketsGeographic scope

    Coverage Criteria for Non-Preferred Oncology Products

    Approval criteria for non-preferred products

    Non-preferred products may be approved when ALL of the following are met:

    Non-preferred approval conditions: The individual has had an adequate therapeutic trial of preferred product(s).typically six months from first dose at FDA or compendia-based therapeutic doses

    Adequate therapeutic trial is typically defined as six months from first dose at FDA or compendia-based therapeutic doses of preferred product; new therapy = no previous utilization within the last 180 calendar days.

    Non-preferred approval conditions: There is documented drug therapy failure or intolerance to the preferred product(s).

    Documentation of drug therapy failure or intolerance to preferred products is required for approval.

    Non-preferred approval conditions: Any required prior authorization criteria for the specific drug are satisfied.

    Certain drugs may require prior authorization to ensure safe and effective use; prior authorization requirements must be met.

    This policy does not enumerate clinical exclusions beyond the plan's product preference. It establishes preferred and non-preferred oncology products to guide coverage decisions and prior authorization, and notes that preferred product lists may change with market events such as new approvals or withdrawals.

    The document does not list discrete "not medically necessary" scenarios. Instead, requests for non-preferred products require documentation that the member had an adequate therapeutic trial of preferred product(s) and experienced documented drug therapy failure or intolerance before approval will be considered. An adequate therapeutic trial is typically defined as six months at FDA- or compendia-based therapeutic doses, and new therapy is defined as no utilization in the prior 180 calendar days.

    Relevant Product and Billing Codes

    Bevacizumab / related product codesmixed
    J9035bevacizumab (listed as non-preferred in places)
    Q5107HCPCS/Q-code referenced in bevacizumab group
    Q5118HCPCS/Q-code referenced in bevacizumab group
    Q5126HCPCS/Q-code referenced as non-preferred
    Q5129HCPCS/Q-code referenced as non-preferred
    Rituximab / related product codesmixed
    J9312rituximab (listed as non-preferred in places)
    Q5115HCPCS/Q-code referenced with rituximab products
    Q5119HCPCS/Q-code referenced with rituximab products
    J9311rituximab (alternate code listed)
    Trastuzumab / related product codesmixed
    J9355trastuzumab (listed as non-preferred in places)
    J9356trastuzumab (alternate code listed)
    Q5116HCPCS/Q-code referenced with trastuzumab products
    Q5117HCPCS/Q-code referenced with trastuzumab products
    Colony stimulating factors (pegfilgrastim, filgrastim) codesmixed
    J2506pegfilgrastim (listed in supportive care colony stimulating factors section)
    Q5108HCPCS/Q-code referenced with pegfilgrastim products
    Q5111HCPCS/Q-code referenced as non-preferred
    Q5101HCPCS/Q-code referenced with filgrastim products
    J1442filgrastim (Neupogen) listed as non-preferred
    J1449HCPCS code referenced
    Denosumab / related product codesmixed
    J0897denosumab (Xgeva/Prolia) listed in supportive care section
    Q5136HCPCS/Q-code referenced as non-preferred denosumab biosimilars
    Q5158HCPCS/Q-code referenced
    Q5162HCPCS/Q-code referenced

    Prior Authorization, Step Therapy, and Documentation Requirements

    Documentation Required

    Therapeutic Trial Documentation

    Certain oncology and oncology-related drugs require prior authorization. For requests for non-preferred products to be approved, the member must have had an adequate therapeutic trial of preferred product(s) with documented drug therapy failure or intolerance.

    • Adequate therapeutic trial is typically defined as six months (180 days) from first dose of therapy at FDA- or compendia-based therapeutic doses of the preferred product.
    • New therapy is defined as no previous utilization within the last 180 calendar days.
    • Requests for non-preferred products require documentation of intolerance or treatment failure to preferred product(s).
    Step Therapy

    Step Therapy for Non-Preferred Products

    Step therapy is enforced for non-preferred products. Approval of non-preferred agents generally requires documented trial and failure or intolerance of the applicable preferred product(s) before coverage will be granted.

    Policy Background

    Highmark defines preferred and non-preferred oncology products across biologic reference agents, biosimilars, and supportive-care therapies. The policy explicitly groups agents such as anti-VEGF, anti-CD20, and anti-HER2 reference and biosimilar products, as well as colony-stimulating factors (pegfilgrastim and filgrastim) and denosumab formulations, into preferred/non-preferred listings to guide formulary selection and prior authorization.

    Key Definitions

    Adequate therapeutic trial
    DefinitionAdequate therapeutic trial is typically defined as six months from first dose of therapy at FDA or compendia-based therapeutic doses of a preferred product.
    PurposeEstablishes timeframe for judging treatment exposure before considering non-preferred product approval.
    Documentation requiredMedical record must show start date and dosing consistent with FDA or compendia recommendations to confirm the 6-month trial.
    New therapy
    DefinitionNew therapy = no previous utilization within the last 180 calendar days.
    ImplicationTherapies with any use within prior 180 days are not considered 'new' for step-therapy/coverage decisions.
    Policy Summary
    PayerHighmark West Virginia
    PolicyPreferred Oncology Products (biosimilars and supportive care agents) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor non-preferred oncology products submit prior authorization with documentation of an adequate therapeutic trial (typically six months) and evidence of failure or intolerance to preferred products.
    SourceLink
    On This Page
    Coverage Criteria for Non-Preferred Oncology ProductsRelevant Product and Billing CodesPrior Authorization, Step Therapy, and Documentation RequirementsPolicy BackgroundKey Definitions
  1. Provider must document the preferred product(s) tried, dates of therapy, dose, and reason for discontinuation (e.g., lack of efficacy or adverse effect).
  2. If the member cannot tolerate the preferred product for a clinically valid reason, provide supporting clinical documentation.
  3. Preferred product lists are subject to change; verify current preferred agents at the time of request.
  4. Prior Authorization

    Prior Authorization and Denial Risk

    Prior authorization may be required for certain oncology agents to ensure safe and effective use. Failure to provide adequate therapeutic trial documentation or step-therapy information may result in denial of the non-preferred drug request.

    • Prior authorization is required for certain drugs — confirm requirement at time of submission.
    • Incomplete documentation of a six-month therapeutic trial or missing evidence of intolerance/failure increases risk of denial.
    Use in authorizationUsed to determine eligibility for preferred product trial requirements and prior authorization assessments.